Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19
Authors:
- Elise Klement-FrutosEKElise Klement-Frutos
- Sonia BurrelSonia Burrel
- Gilles PeytavinGPGilles Peytavin
- Stéphane MarotSMStéphane Marot
- Minh P. LêMLMinh P. Lê
- Nagisa GodefroyNGNagisa Godefroy
- Vincent CalvezVCVincent Calvez
- Anne-Geneviève MarcelinAMAnne-Geneviève Marcelin
- Eric CaumesECEric Caumes
- Valérie PourcherVPValérie Pourcher
- David BoutolleauDBDavid Boutolleau
- 1 January 2021
- journal article
- letter
- Published by Elsevier in Journal of Infection
- Vol. 82 (1) , 159-198
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infectionmedRxiv, 2020
- Covid-19 — Navigating the UnchartedNew England Journal of Medicine, 2020
- Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCREurosurveillance, 2020
- Drug targets for corona virus: A systematic reviewIndian Journal of Pharmacology, 2020
- Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective studyThe Lancet, 2003